Skip to content

16% of drug-naive entering GSK US studies already have resistance

Suspected abacavir hypersensitivity less likely to be diagnosed in people of African ethnicity

No fat loss with tenofovir after five years

Study challenges current thinking regarding viral load as a predictor of CD4 cell loss

Studies suggest possible benefits of treating primary HIV infection

Severe immune suppression linked to poorer CD4 cell response with virologically successful HAART

Draft BHIVA treatment guidelines: respond by Monday September 4th

Final results confirm twice-daily boosted fosamprenavir is comparable to twice-daily Kaletra in treatment-naive

Large analysis shows benefits of starting treatment with efavirenz